Norma Cameli

Norma Cameli

Auto-generated profile, based on publicly available information

Norma Cameli

San Gallicano Dermatological Institute – IRCCS

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2012 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Gabriella FabbrociniGabriella Fabbrocini
Gabriella Fabbrocini
NCNorma Cameli
Norma Cameli
MRMaria Concetta Romano
Maria Concetta Romano
MMMaria Mariano
Maria Mariano
LPLuigia Panariello
Luigia Panariello
GMGiuseppe Monfrecola
Giuseppe Monfrecola
New chemotherapic agents and new protocols in oncology have led to an increasing survival rate in patients affected by tumors. However, this increased use has been accompanied by a growth in the incidence of cutaneous side effects and a worsening of patients’ quality of life. Appropriate management of skin toxicity associated with chemotherapic agents is therefore necessary for suitable drug administration and to improve quality of life and clinical outcomes.

1 July 2014
Verified
Journal Article
Closed access
NCNorma Cameli
Norma Cameli
EAElva Abril
Elva Abril
MMMaria Mariano
Maria Mariano
Enzo BerardescaEnzo Berardesca
Enzo Berardesca
Melasma is a common acquired pigmentary disorder that has a considerable psychological impact on the patient. The recurrent and refractory nature of this condition makes it difficult for treatment. We aim to evaluate the efficacy and safety of a combined system that simultaneously uses monopolar radiofrequency (RF) and transdermal drug delivery of phytocomplex containing 1% kojic acid in the treatment of melasma. Fifty patients affected by melasma underwent 6 sessions of treatment at 1-week intervals. The outcome was evaluated before treatment (T0) and 1 month (T1) and 6 months (T2) after treatment using the Melasma Area and Severity Index score, a Mexameter, and Visioface devices for digital and ultraviolet computerized image analysis of skin color. The image analysis showed that hyperpigmentation was significantly reduced at T1 and T2 compared with baseline. Melasma Area and Severity Index score, the average melanin score, and the average erythema values showed a significant reduction. No side effects were observed or reported. This study describes the first report of improvement in melasma through the combined use of monopolar RF with transdermal delivery of depigmenting agents. This could be a safe, tolerable, and effective alternative tool for the treatment of melasma.

1 January 2017 in Australasian Medical Journal
Verified
Journal Article
Closed access
Sara CacciapuotiSara Cacciapuoti
Sara Cacciapuoti
AMAnna Masara
Anna Masara
MMMaria Mariano
Maria Mariano
NCNorma Cameli
Norma Cameli
Gabriella FabbrociniGabriella Fabbrocini
Gabriella Fabbrocini


18 May 2012
Verified
Book Chapter
Closed access
PDF file
NCNorma Cameli
Norma Cameli
GCGiovanni Cannarozzo
Giovanni Cannarozzo
PBPaolo Bonan
Paolo Bonan
NBNicola Bruscino
Nicola Bruscino
PCPiero Campolmi
Piero Campolmi